Exploring Strategies to Define Direct Vs Indirect Target Engagement with Glioblastomas
11:00 am - Tuesday 17th February 2026
- Join this workshop to establish a clear framework for defining direct target engagement direct vs indirect target engagement
- Navigating the application of cutting-edge preclinical methodologies to confirm on-target binding with GBM cells such as mass spectrometry, thermal shift assays and radiolabels compounds for PET imaging to visualize drugtarget engagement.
- Analyzing changes in signalling pathways, gene expression and immune cell phenotypes within the GBM tumour microenvironment
- Advancing biomarker tracking within the blood-brain barrier to track drug effect with ctDNA and immune markers
- Deepening the understanding of direct vs indirect engagement to understand the design rationale of combination therapies
- Driving the analysis of PK/PD markers to monitor the emergence of drug resistance in recurring GBMs
